### Supplementary table.

| No. | Age (yrs) | Gender | Previous statin exposure | Serology besides anti-HMGCR | Anti-HMGCR positivity | Time from treatment initiation to sampling (months) | Phenotype | Extra-muscular involvement | CK at the first assessment (times upper normal range) | MMT8 at the first assessment (0-80) | Main biopsy findings | Treatment ever | Treatment at the last assessment | Outcome |
|-----|-----------|--------|--------------------------|-----------------------------|------------------------|----------------------------------------------------|-----------|---------------------------|--------------------------------------------------|--------------------------------|-------------------|---------------|-------------------------------|----------|
| 1.  | 75        | Male   | Yes                      | Ro60, Ro52                  | Weak                   | 0                                                  | PM        | H                         | 2                                                | 78                             | NF, RGF, FSV, PMA, Ei, MHC | GCS, MTX     | GCS 10mg                       | Chronic active |
| 2.  | 70        | Female | No                       | -                            | Strong                 | 0                                                  | DM        | ILD, S, R, D              | 25.3                                             | 55                             | NF, RGF, FSV, MHC             | GCS, AZA, CYC, RTX   | AZA 50mg, GCS 2,5mg            | Remission |
| 3.  | 70        | Female | Yes                      | -                            | Strong                 | 0                                                  | PM        | -                         | 25.2                                             | 61                             | NF, RGF, FSV, MHC             | GCS, AZA, RTX, MMF, IVIG | GCS 10mg                       | Chronic active |
| 4.  | 64        | Female | No                       | NXP2, FH1L                   | Weak                   | 0                                                  | DM        | S                         | Normal                                           | 77                             | NF, RGF, FSV, PFA, MHC       | GCS, AZA, MMF            | MMF 2g, GCS 2,5mg             | Remission |
| 5.  | 58        | Male   | No                       | Jo-1, SSA                   | Strong                 | 0                                                  | PM        | -                         | 27                                               | 68                             | NF, FGF, SI, EI, PI, MAC, MHC | GCS, MTX     | none                          | Drug free remission |
| 6.  | 54        | Female | No                       | -                            | Strong                 | 0                                                  | PM        | D                         | 2.5                                              | 67                             | NF, RGF, SI, FSV             | GCS, MTX, AZA, CYC, IVIG, MMF | MMF 2g/kg/month, GCS 2,5mg   | Chronic active |
| 7.  | 52        | Female | No                       | TIF1-γ                      | Strong                 | 16                                                 | DM        | S, D                      | Unknown                                          | -                              | NF, RGF, MHC                 | GCS, MTX     | Death due to malignancy        | Death due to malignancy |
| 8.  | 51        | Female | No                       | Jo-1, Ro60, Ro52            | Weak                   | 118                                                | DM        | ILD, S, R, A              | Normal                                           | 71                             | FSV                            | GCS, AZA     | none                          | Drug free remission |
| 9.  | 48        | Female | No                       | -                            | Weak                   | 86                                                 | PM        | -                         | 1.2                                              | 59                             | NF, FSV                       | GCS, AZA     | GCS 6.25mg                    | Chronic active |
| 10. | 47        | Female | No                       | -                            | Strong                 | 73                                                 | PM        | -                         | 2.2                                              | -                              | NF, RGF, FSV, PFA            | GCS, MTX, AZA, IVIG         | none                          | Low disease activity |
| 11. | 47        | Female | No                       | -                            | Weak                   | 11                                                 | PM        | H, R, D                   | 1.7                                              | 69                             | RGF, SI, PI, MHC             | GCS, MMF, IVIG            | MMF 2g, GCS 5mg              | Chronic active |
| 12. | 37        | Female | No                       | -                            | Strong                 | 0                                                  | PM        | S                         | 1.8                                              | 76                             | FSV                            | GCS, AZA, IVIG          | none                          | Low disease activity |
| 13. | 28        | Female | No                       | ACA                         | Weak                   | 0                                                  | DM        | S, R                      | Normal                                           | 80                             | SI, PI, PFA, MHC             | HHQ                     | none                          | Drug free remission |

CK – creatine kinase, MMT8 – manual muscle test of 8 muscle groups, PM – polymyositis (including IMNM), DM – dermatomyositis, GCS – glucocorticoids (prednisone), AZA – azathioprine, MMF – mycophenolate mofetil, MTX – methotrexate, IVIG – intravenous immunoglobulins, RTX – rituximab, HHQ – hydroxychloroquine, ACA – anti-centromere antibody, ILD – interstitial lung disease, S – skin lesions, R – Raynaud’s phenomenon, A – arthritis, D – dysphagia, NF – necrotic fibers, RGF – regenerating fibers, FSV – fiber size variation, PMA – perimysial atrophy, Ei – endomysial inflammatory infiltrates, PI – perimysial inflammatory infiltrates, SI – scattered inflammatory infiltrates, MAC – membrane attack complex, MHC – major histocompatibility complex class I upregulation.

doi: 10.3389/fimmu.2022.866701